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ABSTRACT
ADENOVIRUS-INDUCED CYCLIN E ACTIVATES CDK2 FOR VIRUS
REPLICATION
Pei-Hsin Cheng
February 2, 2010
Human adenoviruses (Ads) can infect and replicate in cells at different
cell-cycle stages. Ads with the E1 B55K deletion preferentially replicate in cancer
cells and cause oncolysis. Our laboratory has previously shown that the Ad E1 b
gene is involved in induction of several cell-cycle regulative genes (Rao, X. et al.
Virol. 350:418-28, 2006) and that cyclin E expression is required for efficient viral
replication (Zheng, X. et al. J Viral 82:3415-27, 2008). In this study, we sought to
investigate the interaction of cyclin E with its partner CDK2 in Ad-infected cells.
We show four lines of evidence indicating the importance of CDK2 activation by
cyclin E in Ad replication. First, the replication of E1 B55K-deleted Ads was
partially inhibited in the transgenic CHO cell line expressing a cyclin E mutant
unable to bind CDK2, but not in those expressing wild-type cyclin E or a mutant
unaffecting its CDK2 binding. Second, Ad-induced cyclin E protein formed com-

v

plex with CDK2, correlating with the increased phosphorylation of CDK2 at T160
and pRb at 8612. Third, the CDK2 chemical inhibitor, roscovitine, decreased viral
DNA synthesis, protein production, and viral yield. Finally, a siRNA specifically
inhibiting CDK2 repressed the viral replication with the decrease in pRb
phosphorylation. Our findings indicate that Ad-induced cyclin E activates CDK2 to
target the transcription repressor pRb for Ad productive replication.
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CHAPTER I
INTRODUCTION
The human adenoviruses (Ads) are double-stranded linear DNA viruses that
can infect and replicate in cells at different cell-cycle stages (5). After infection,
viral early proteins interact with cellular factors to create favorable environments
for viral replication. The E1 region contains two sets of genes, E1a and E1b, that
are dedicated to controlling cell cycle, inhibiting apoptosis, and regulating cellular
and viral genes (69). Ads with E1 modifications that preferentially replicate in
cancer cells have been used for oncolytic virotherapy.

The viral E1 a gene expresses immediately after infection. The primary role of
E1A products is to regulate expression of multiple cellular and viral genes (5).
Instead of directly binding to specific DNA sequences in transcriptional regulation
elements, E1A proteins interact with several key regulators of cell proliferation (3,
20). The well-known cellular factors that E1A proteins bind with are products of
the retinoblastoma (Rb) gene and its structurally related genes, p107 and p130
(41, 76). By sequestering the retinoblastoma protein (pRb), E1A activates
transcriptional regulator E2F proteins. Studies have suggested that the pRb/E2F
complex actively represses the transcription from target genes, mediates G1
arrest triggered by p19 (ARF), p53, p161NK4a, TGF beta, and cell contact (38,64,
83). Several groups have shown that expression of E1A triggers the accumulation
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of p53 protein and p53-dependent apoptosis (16, 40, 44, 86) either by activating
p53 transcription or preventing p53 from being degraded by the proteasome (11,
16,40,56).

E1 B55K has been shown in some studies to counteract the E1A-induced
stabilization of p53 (16, 58). E1 B55K protein may inhibit the functions of p53
through at least two distinct mechanisms. E1 B55K reportedly binds the amino
terminus of p53 (35), and this binding may repress p53 transcriptional activation,
as suggested in transcription assays (43) and transient transfection studies (79).
E1B55K may also interfere with p53 function by cooperating with viral E40rf6
protein to cause proteolytic degradation of p53 protein (29, 51, 57, 77). Thereby,
E1 B55K blocks the expression of p53-regulated genes and, consequently,
counteracts the p53-dependent apoptosis induced by E1A, allowing efficient viral
replication (35, 43).

Ad dl1520 (ONYX-015) contains an 827-bp deletion and a point mutation
generating a premature stop codon in the E1 B55K coding sequence, preventing
expression from the gene (4). It was originally proposed that the E1B55K-deleted
Ads

could

only

replicate

in

p53-deficient

tumor

cells

because

the

E1 B55K-mediated degradation of p53 protein might be not required in those
cancer cells (8, 62). E1 B55K-deleted oncolytic Ads have been applied in human
clinical trials and are being marketed for cancer treatment in China (80). However,
the original hypothesis was challenged by several studies showing E1 B55K
mutants are able to replicate in many cancer cell lines regardless of their p53
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status (17, 26, 27, 63). Recent studies have shown that the accumulation of p53
protein in cells, after infection with Ads carrying mutated E1 855K genes that are
unable

to

repress

p53,

can

neither

efficiently

induce

apoptosis

nor

transcriptionally activate expression of p53-responsive genes (32, 52). These
studies have demonstrated that blocking of p53 activity by E 1855K protein is
unlikely to be the major requirement for viral replication. Thus, the mechanism(s)
of E1 855K-deleted viral replication of in cancer cells is still not established, even
though the vectors have been applied in human cancer treatment (80).

Previously, our laboratory has shown that Ad E1855K is involved in the
induction of cell cycle-related genes, including cyclin E (60). E1855K-mediated
cyclin E induction normally plays a critical role in viral replication; however,
E1855K is not required for cyclin E induction and viral replication in cancer cells
with deregulated cyclin E (85). We proposed that cyclin E deregulation in cancer
cells may be an important molecular basis for oncolytic replication of
E1 855K-deleted Ads (85).

Cyclin E regulates the DNA replication (14, 22), centrosome duplication (31,
45), and cell cycle progression in cells. In normal cell cycle, the level of cyclin E
rises at late G1 phase and peaks at the G1/S phase to promote the S-phase entry
(37, 54). Deregulation of cyclin E is frequently detected in many types of cancers
by gene amplification (42), overexpression of cyclin E mRNA or protein levels (18,
66), decrease of cyclin E turnover (73), and the presence of more active forms of
cyclin E (2, 36, 78). Constitutive overexpression of cyclin E was shown to induce
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chromosome instability and impair normal cell cycle progression (47, 72). The
idea that abnormal cyclin E expression can trigger tumors has also been
supported by several transgenic animal studies (10, 21, 39).
One of the functions of cyclin E in the cell cycle is to bind and activate
cyclin-dependent kinase 2 (CDK2) (50). The cyclin E/CDK2 complex then
phosphorylates substrates such as pRb and leads to transcriptional activation of
downstream genes. Recent studies have indicated that cyclin E also has
CDK2-independent functions (23, 24). In vivo animal studies revealed the
variance between the phenotypes of cyclin E null (cyclin Er'- ET'-) mice and
CDK2 null (CDK2-'-) mice. Mice lacking CDK2 are viable, showing no significant
effects on normal development except defective germ cell development (6, 55).
Yet double knockout of cyclin E1 and E2 genes in mice caused embryonic lethality
owing to the deficiency in endoreplication of trophoblast giant cells and
megakaryocytes (25).

Matsumoto et al.

(2004) identified a centrosomal

localization signal (CLS) domain in cyclin E (46). This CLS domain allows cyclin E
to target the centrosome and promote S phase entry in a CDK2-independent
manner. Additionally, Geng et al. (2007) showed that a cyclin E kinase-deficient
mutant (KD-E) is able to partially restore minichromosome maintenance protein
(MCM) loading and S phase entry in cyclin E null cells (24). These results
illustrate the CDK2-independent functions of cyclin E.

To further study the role Ad-induced cyclin E in the Ad infectious life cycle, we
investigated whether the cyclin E function is dependent on activation of CDK2.
This question may be especially important in the development of oncolytic
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virotherapy strategies. We show that Ad-induced cyclin E binds with and activates
CDK2 that targets transcription repressor pRb, which may in turn regulate
expression of cellular and viral genes. The results suggest that the interaction
between cyclin E and CDK2 generates a suitable environment for Ad productive
replication.
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CHAPTER II
MATERIALS AND METHODS
Cell lines and culture conditions. HEK 293 (ATCC no. CRl-1573), CHO (ATCC
no. CCl-61) and human lung cancer A549 (ATCC no. CCl-185) cell lines were
purchased from the American Type Culture Collection (Rockville, MD). The
transgenic CHO cell lines were established and kindly provided to us by Dr.
James L. Maller's laboratory (46). HEK 293 and A549 cell lines were cultured in
MEM-Alpha. All CHO cell lines were cultured in F-12K medium. All media were
supplemented with 10% FBS and penicillin/streptomycin (100 U/ml). Cells were
cultured in a 5% CO2 incubator at 3rC. All cell culture reagents were obtained
from Gibco BRl (Bethesda, MD).

Adenoviral vectors. Wild-type adenovirus type 5 (Adwt, ATCC no. VR-5) was
used as a replication-competent control. AdCMV/GFP, an Ad vector with E1
deletion, was used as a replication-defective control. Adhz63, an oncolytic Ad
vector with the deletion of E1 B55K region similar to d11520, was constructed by
our laboratory (59).

Viral infection and titration. Cells were seeded into 6-well plates at a density of
2.5 x10 5 (cells/well) and cultured under the indicated conditions. Subsequently,
cells were mock-infected or infected with AdGFP, Adwt, or Adhz63 at an MOl of 5.
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Cytopathic effect (CPE) caused by viral replication was observed at designed time
points and photographed with an inverted microscope (Olympus CKX41). Total
infected cells and cell supernatants were collected at 48 hr postinfection (p.i.) and
lysed to release virus particles with three cycles of freezing and thawing. The viral
titers were determined by the infective unit method as described previously (65,
84). Briefly, HEK 293 cells were seeded in 96-well plates at a density of 103
(cells/well) and then infected with 5-fold serially diluted viruses. CPE was
recorded and scored after incubation for 7 days.

Viral DNA synthesis assay. After viral infection, A549 cells were collected at
different time points. The viral DNA synthesis was determined with Southern blot;
1 I-Ig of isolated genomic DNA was digested with the restriction enzyme Pstl and
analyzed with 1% agarose gel, which was subsequently transblotted to a
Hybond-N+ membrane (YA3609; Amersham Pharmacia Biotech, Arlington
Heights, IL). The probe was prepared by digesting 0.5 I-Ig pBHGE3 (7) with Pstl
and labeled by following the protocol of Amersham AlkPhos Direct Labeling and
Detection Systems (RPN 3690; GE Healthcare, Piscataway, NJ). The blot was
prehybridized for 3 hrs at 60°C. The hybridization and stringency washes were
performed at 60°C and followed by the chemiluminescent detection according to
the manufacturer's protocol.

Western blot analysis. Infected A549 cells were harvested at indicated time
points and lysed with CDK2 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCI, 5 mM
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MgCb, 0.5% Nonidet P-40, 0.1 % Brij 35, 5 mM sodium glycerophosphate, 1 mM
sodium vanadate, 1 mM dithiothreitol). The Western blot analyses were
performed as described previously (86). Briefly, 80 I-Ig of cell Iysates were
electrophoresed through 12% SOS-polyacrylamide gels and transferred onto an
Immobilon-P Membrane (Millipore, Billerica, MA). The primary antibodies used in
this study were rabbit anti-cyclin E (M-20), COK4 (C-22), mouse anti-cyclin 01
(OCS-6), PCNA (PC1 0), p21 (F-5), pRb (IF8) (Santa Cruz Biotechnology, Santa
Cruz, CA), mouse anti-COK2, p27 (BO Biosciences, San Jose, CA), pCOK2 T160
(Cell signaling Danvers, MA), rabbit anti-phospho-pRb S612, and actin (Sigma, St.
louis, MO), anti-phospho-pRb S795 (New England Biolabs, Beverly, MA), and
anti-phospho-pRb T821 (Invitrogen, Carlsbad, CA). The membranes were then
incubated

with

anti-mouse

immunoglobulin

G

(lgG)

or anti-rabbit

IgG

peroxidase-linked species-specific whole antibody (GE Healthcare, Piscataway,
NJ). Chemiluminescent detection was performed with ECl reagents according to
the supplier's recommendations (GE Healthcare).

Immunoprecipitation. A549 cells were seeded in 150 mm dishes at a cell density

of 5 x10 6 (cells/dish) and then mock-infected or infected with AdGFP, Adwt, or
Adhz63 at an MOl of 5. At 48 hr p.i., cells were collected and lysed with COK2
lysis buffer according to the method described in previous publications (12, 85).
500l-lg cell Iysates were immunoprecipitated with cyclin E (HE111), the mouse
monoclonal antibody, (Santa Cruz) or anti-COK2 antibody (BO Transduction
laboratories) at 4°C for 4 hr, followed by adding protein A Sepharose Cl-4B
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(82506; Sigma) and incubating overnight. Immunocomplexes were analyzed by
Western blot with anti-cyclin E and CDK2 antibodies.

siRNA transfection.

The

siRNA oligonucleotides

were

synthesized

by

Eurogentec (Fremont, CA). Three different siRNA duplexes were designed to
target CDK2 on nucleotides 399 to 419 (#1), 619 to 639 (#2), and 691 to 711 (#3)
according to Genbank accession NM001798.2 (National Center for Biotechnology
Information GenBank). A negative control siRNA duplex containing two strands of
19 complementary RNA bases with 3'dTdT overhangs was obtained from
Eurogentec (SR-CLOOO-005). The sequences have no significant homology to
any known mouse, rat, or human gene sequences. A549 cells were seeded into a
6-well plate at a density of 105 (cells/well) and then transfected with 200 nM CDK2
siRNA duplexes or a negative control siRNA duplex with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Cells were
harvested at 48 hr after transfection. Eighty j.Jg of cell Iysates were analyzed by
Western blot with CDK2 and actin antibodies.
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CHAPTER III
RESULTS
Cyclin E mutant unable to bind CDK2 inhibits replication of E1 B55K-deleted
virus.
Our laboratory has previously established the link between cyclin E and
replication of E1 B55K-deleted viruses (85). Cyclin E can promote S phase entry
and

participate

in

DNA

replication

via

CDK2-dependent

(50)

and

CDK2-independent pathways (46). To investigate the connection of CDK2 and
cyclin E in Ad replication, we first applied transgenic CHO cell lines expressing
Myc-tagged wild-type rat cyclin E (cycE-wt), a cyclin E mutant that is still able to
bind CDK2 (cycE-SWNQ-A), or a cyclin E mutant unable to bind CDK2
(cycE-S180D) (46) to evaluate whether cyclin E binding with CDK2 plays a role in
viral replication. Expression of the knock-in cyclin E genes is under the control of
the tetracycline-on (Tet-on) system. We first examined the protein levels of the
Myc-tagged cyclin E proteins with or without tetracycline as an expression inducer.
The results showed that the expression of knock-in rat cyclin E genes is not
significantly repressed in the absence of Tet (Fig. 1A). Thus, the CHO cell line
without any transgenic cyclin E was used as a control for the CHO cell lines with
different knock-in cyclin E genes.
To verify the infectivity of human Ad on the hamster cells, the normal CHO
cells and the three transgenic CHO cells were infected with AdGFP at an MOl of
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10. AdGFP is a replication-defective Ad with deletion of E1a and E1b genes and
carrying green fluorescent protein (GFP) as a reporter gene. Equal expression of
the green fluorescence protein was observed in all four cell lines at 48 hr p.i.,
indicating that all the CHO cells can be efficiently and equally infected by Ads (Fig.
1B).

We then determined the CPE caused by viral replication in the cells infected
with wild-type Ad5 (Adwt) or E1B55K-deleted Adhz63 at an MOl of 10. The
repeated experiments showed that there was no difference among the
Adwt-caused CPE in the normal CHO and the three transgenic cell lines at 96 hr
p.i., showing cells rounded up and detached from the cell monolayer (Fig. 2, a-h).
However, CPE caused by E1 B55K-deleted Adhz63 was repressed in the CHO
(Fig. 2, i and j) and in the CHO-cycE-S180D cells (Fig. 2,

0

and p). The CHO cells

do not express any transgenic cyclin E, while the transgenic cycE-S180D is
unable to bind CDK2. More CPE was observed in Adhz63-infected CHO cells
expressing cycE-wt (Fig. 2, k and I) or cycE-SWNQ-A (Fig. 2, m and n), both of
which are able to bind with CDK2.
It should be noted that all the CHO cells carry their endogenous cyclin E gene.
It appeared that the endogenous cyclin E was enough to support Adwt replication
in CHO cells, but overexpression of transgenic cyclin E that can bind with CDK2
improved replication of Adhz63 with deletion of E1 B55K. This result agrees with
our previous report that oncolytic replication of E1 B55K-deleted viruses is
dependent on overexpression or deregulation of cyclin E in cells (85). The results
presented in Figure 2 suggest that cyclin E binding to CDK2 is required for viral
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replication.

Cyclin E/CDK2 complex is induced by replication-competent viruses.

Our laboratory has reported that A549 cells constitutively express cyclin E
protein, and that Ad infection mainly induces the large form of cyclin E protein
(cyclin EL) (85). Cyclin E and cyclin EL are generated from splicing and using
different start ATG codons in exons 2 and 3 (54). The N terminus of cyclin EL is 15
amino acids longer than that of cyclin E. To investigate the physical interaction
between CDK2 and cyclin E, we used anti-cyclin E antibody to immunoprecipitate
cyclin E protein and analyzed the immunocomplexes with Western blot. A549
cells were mock-infected or infected with AdGFP, Adwt, or Adhz63. At 48 hr p.i.,
cells were collected and lysed. The data show that cyclin E precipitated from cells
mock-treated or treated with replication-defective AdGFP (as controls) did not
exhibit significant association with CDK2 protein (Fig. 3A, lanes 1 and 2).
However, immunocomplexes from Adwt- and Adhz63-infected A549 cells
contained both cyclin E and cyclin EL with an increase of CDK2 binding (Fig. 3A,
lanes 3 and 4). Thus, the cyclin EL induced by viral replication is associated with
CDK2 in the precipitated complex. To verify this cyclin E/CDK2 interaction, we
also used anti-CDK2 antibody to pull down the protein complex and examined the
level of cyclin E. The immunoprecipitated CDK2 protein was increased in Adwt
and Adhz63-infected cells with a concomitant precipitation of cyclin EL, especially
for Adwt-infected cells (Fig. 38, lanes 3 and 4). The results indicate that
replication-competent viruses (Adwt and Adhz63) induce cyclin EL expression
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and increase the formation of cyclin E/CDK2 complex.

Adenoviruses activate cyclin E/CDK2 but not cyclin D/CDK4.

Consistent with the previous published study in our laboratory (85), we
detected that the faster-migrating band, cyclin E, was constitutively produced by
A549 cells and that the slower-migrating band, cyclin EL, was markedly induced
by the replicative Adwt and Adhz63 (Fig. 4A, lanes 3 and 4, 7 and 8). Previous
studies showed that the CDK2 is activated by the phosphorylation on the T160
site and that this phosphorylation increases its electrophoretic mobility, resulting in
faster-migrating bands (28). Analysis of the cell Iysates with Western blot
demonstrated that the cyclin

EL induction led to an increase of the

faster-migrating CDK2, consistent with pCDK2 T160 (the active form of CDK2),
which is significantly increased at 48 hr p.i. (Fig. 4A, lanes 7 and 8). We verified
that the phosphorylated pCDK2 T160 was increased by Adwt and Adhz63 with the
antibody that specifically targets this phosphorylated CDK2 protein (Fig. 48).
We also examined the level of cyclin D since both cyclin D and cyclin E are
involved in the transition of the G1/S phase. Interestingly, the cyclin D level was
decreased after viral infection (Fig. 4C, lanes 3 and 4, and 7 and 8). Meanwhile,
the level of CDK4 and the proliferating cell nuclear antigen (PCNA) did not
significantly change in any of the groups. CDK4 is regulated and activated by
cyclin D to process the G1-S transition (34, 70). PCNA is known to regulate DNA
replication and DNA repair, and is also associated with multiple cyclin/CDK
complexes in the cell-cycle progression (48, 82). Our results show that Ads
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specifically activate cyclin E and CDK2, but not cyclin D and CDK4, suggesting a
critical role for cyclin E and CDK2 in Ad replication.

Adenoviruses increase pRb phosphorylation and repress CDK inhibitors.

CDK2 activated by cyclin E is known to control the G1-S transition by
phosphorylation of the downstream substrates. Considering that pRb is one of the
well-known targets for pCDK2, we examined whether the increase of active
pCDK2 alters the phosphorylation of pRb on S612, which is a CDK2-preferred
phosphorylation residue (67, 81). We found that phospho-pRb S612 was strongly
increased in cells infected with replication-competent Adwt and Adhz63, even
though the protein level of unphophorylated pRb is decreased approximately two
fold (Fig. 5A, lanes 3 and 4). We could not detect any significant changes of pRb
phosphorylation at the CDK2-prefferred phosphorylation residue T821 (33, 81)
and the CDK4-prefferred S795 (13) (Fig. 5A), suggesting the specific selection of
pRb phosphorylation at S612 by CDK2. We also observed that the protein levels
of both p21 and p27 are decreased in the virus-infected cells, especially for p21
which is strongly inhibited (Fig 58, lanes 3 and 4, and 7 and 8). p21 and p27 are
the well-known CDK inhibitors, which negatively regulate the activity of
cyclin/CDK complexes to prevent the cell-cycle progression (71). Our results
suggest that Ads activate the CDK2 by inducing cyclin E and repressing p21 and
p27, and that the cyclin E-activated CDK2 in turn increases pRb phosphorylation
at S612 to promote viral production.
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CDK2 chemical inhibitor reduces adenoviral replication.

To further investigate the role of CDK2 in viral replication, we used the
chemical CDK2 inhibitor, roscovitine (Ros; CYC202), to interrupt cyclin E and
CDK2 interaction. Ros is a purine derivative that inhibits the activity of CDK2 by
binding to its active site (1S). Ros reduces phosphorylation on CDK2 (61) and
blocks the androstenedione-induced increase in active phosphorylated CDK2 (1).
If CDK2 is required for viral replication, blocking CDK2 activity should reduce
replication. Figure 6A, representing one of the three repeated experiments, shows
that with increased Ros, CPE caused by infection with Adwt and Adhz63 was
partially inhibited. Figure 68 shows that S IJM of Ros led to a 2-fold decrease of
Adwt titer (P

=2.17E-04) and a 3.S-fold decrease of Adhz63 titer (P =0.034) when

compared with the control group treated with virus and DMSO. Figure 6 8 also
shows that 10 IJM of Ros led to even more decreases of viral titers, as-fold
decrease for Adwt (P

= 1.01 E-OS) and a 7.S-fold decrease for Adhz63 (P =0.012).

The repressed viral yields are consistent with the CPE phenomenon in Figure 6A.
Thus, inhibiting CDK2 by Ros decreases viral production.
We further examined the levels of viral DNA and proteins produced in cells
affected by Ros treatment. The viral DNA synthesis was determined by Southern
blot probed with the Ad genome (Fig. 7A). The viral DNA synthesis of Adwt and
Adhz63 at 24 hr p.i. was strongly inhibited in the presence of 10 IJM Ros.
Consistently, the viral capsid proteins were significantly inhibited in the presence
of 10 IJM Ros (Fig. 78). We also examined the change of phospho-pRb S612 with
Ros treatment. We found that inhibition of CDK2 activity by Ros repressed the
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phosphorylation of pRb at S612 site induced by Ad infection (Fig. 7C, lanes 4 and
6). Interestingly, Ros treatment markedly repressed cyclin E protein production
induced by Adwt and Adhz63 (Fig. 7C, lanes 4 and 6). To sum up, our data
suggest inhibition of CDK2 with the chemical reagent roscovitine reduced viral
DNA synthesis, capsid proteins expression, phospho-pRb S612 and cyclin E
induction, inhibiting viral replication.

siRNA inhibiting CDK2 represses adenoviral replication by targeting pRb.
Since the chemical inhibitor Ros may also influence other CDKs and cellular
kinases, we applied RNA interference to specifically silenced CDK2 expression in
further experiments. We tested three different pairs of siRNA duplexes targeting
CDK2 on the coding region and showed that all CDK2 siRNAs dramatically
inhibited CDK2 expression in A549 cells (Fig. 8A). The #1 siRNA appears to have
the most sizeable inhibiting effects. To evaluate the effects of CDK2 on the cellular
protein production in response to viral infection, A549 cells were infected with
Adhz63 after the cells treated with CDK2 siRNA duplex (#1) or a non-specific
control siRNA for 48 hrs. We focused on the E1855K-deleted Adhz63 because it
is more sensitive to the inhibition of CDK2 activity as shown in figures 6 and 7. As
expected, the CDK2 siRNA specifically repressed production of CDK2 protein and
decreased pCDK2 T160 (Fig. 88). Repression of CDK2 resulted in reduced
CDK2-specific phosphorylation on pRb, but did not affect pRb protein level (Fig.
88). We also observed that repression of CDK2 specifically decreased
Ad-induced cyclin EL, but not cyclin E. 810ckage of CDK2 expression with siRNA
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notably caused a 3-fold decrease of viral titer (P

=0.03, Fig. BC). These findings

show that specifically inhibiting CDK2 with siRNA significantly represses viral
production, correlating with the decreased CDK2 activation.
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CHAPTER IV
DISCUSSION
Previously our laboratory has shown that induction of cyclin E is required for
Ad replication (60, 85). In this report, we demonstrate that CDK2 activation by
cyclin E is a critical molecular step in Ad replication. Four lines of evidence
support the importance of activation of CDK2 by cyclin E in Ad replication. First,
the replication of E1 B55K-deleted virus was partially inhibited in the transgenic
CHO cell expressing a cyclin E mutant unable to bind CDK2. Second, Ad-induced
cyclin E directly interacted with CDK2 and formed the cyclin E/CDK2 complex,
leading to increased phosphorylation of CDK2 and pRb. Third, the CDK2
chemical inhibitor, roscovitine, decreased viral replication. Finally, a siRNA
specifically inhibiting CDK2 repressed the viral replication with the decrease in
pRb phosphorylation. These four lines of evidence support the hypothesis that
Ad-induced cyclin E activates CDK2, which targets the transcription suppressor
pRb, resulting in controlling cellular and viral gene expression for productive viral
replication (Fig. 9).
Considering that CDK2-independent functions of cyclin E are related to
participation in DNA replication licensing (24) and oncogenic transformation (23),
we first used the CHO cell line expressing transgenic wild-type or mutated cyclin
E genes to investigate whether the ability of cyclin E to bind to CDK2 plays an
important role in the viral replication. Expression of transgenic cyclin E genes did
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not affect Adwt replication. Adwt, containing the intact E1 B55K region, can elicit
endogenous cyclin E expression (60, 85), and, thus, its replication is not
dependent on expression of the transgenic cyclin E genes. However, replication of
the E1 B55K-deleted virus is enhanced in CHO cells expressing transgenic cyclin
E proteins that can bind with CDK2, but not in CHO cells without transgenic cyclin
E or expressing cycE-S180D mutant that is unable to bind CDK2 (Fig. 2).
Consistent with the results of using transgenic CHO cell lines, the CDK2 chemical
inhibitor Ros decreased viral DNA synthesis and protein production (Figs. 6 and
7). Ros inhibits the activity of CDK2 by binding to its active site (15). Our results
suggest that cyclin E binding with and activating CDK2 is an important step in Ad
replication.
Cyclin E and the large form cyclin EL are generated from alternative splicing.
The translation of cyclin EL is initiated at an ATG codon located in exon 2 and
cyclin E is from the ATG codon in exon 3 (54). Previously our laboratory
constructed a plasmid, pTet-cycE, containing cyclin E cDNA that produces these
two forms of cyclin E proteins (85). The A549 cell line constitutively expresses the
regular cyclin E protein (cyclin E), and Ad infection mainly induces the expression
of large form cyclin E protein (cyclin EL) (85). In this study our finding indicates
that Ad-induced cyclin EL preferentially associates with CDK2 protein (Fig. 3). We
cannot exclude that cyclin E in A549 may also interact with CDK2. However, we
only observed detectable levels of CDK2 along with cyclin EL after Ad infection
with replication competent Adwt and Adhz63, suggesting cyclin EL highly interacts
with CDK2. Consistently, Harwell et al. reported that the addition of exogenous
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cyclin EL increases the activity and phosphorylation of CDK2 in vitro (30). They
showed that cyclin EL can bind to endogenous CDK2 in complex with cyclin E,
cyclin A, or unbound CDK2, and the cyclin-activating kinase is involved in the
phosphorylation of CDK2 in this event. It is still unclear why Ad infection mainly
induces cyclin EL that is highly associated with and activates CDK2.
We identified that Ad-induced cyclin EL correlates with the increase of
phosphorylated CDK2 at T160 and phosphorylated pRb at 5612 (Figs. 4A and
5A). Three phosphorylation sites have been identified in CDK2 (28). T160
phosphorylation is essential for CDK2 activity while T14 and Y15 phosphorylation
cause an inhibitory effect. The retinoblastoma tumor suppressor pRb is
inactivated by CDK's phosphorylation and, presumably, enables E2F transcription
factor to be released from the pRb/E2F complex to carry out the downstream
gene regulation (75). Phosphopeptide analysis of pRb showed that 5612 is one of
the CDK2-preferred phosphorylation sites (81). The presence of pCDK2 T160 and
phospho-pRb 5612 provides the evidence to indicate the increased CDK2 activity
caused by Ad-induced cyclin EL. We also examined the level of pRb with
phosphorylation of T821 (CDK2-preffered) and 5795 (CDK4-preffered); however,
we did not detect any significant change on these two sites (Fig. 5A). Inhibition of
CDK2 expression with the CDK2 siRNA repressed phosphorylation on CDK2 and
pRb (Fig. 88) and decreased viral replication (Fig. 8C). Our results indicate that
Ad-induced cyclin EL activates CDK2, which specifically introduces pRb
phosphorylation on 5612 site.
We detected a notable decrease of CDK inhibitors p21 and p27 in the
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Ad-infected cells. The decrease may be the result of the highly induced cyclin
E/CDK2 complex. p21 and p27 inhibit the activity of cyclin/CDK complexes to
prevent the cell-cycle progression, and their protein stability is also regulated by
cyclin/CDK complexes (68, 71, 87). Phosphorylation of p27 by cyclin E/CDK2
causes its degradation (68, 74). Montagnoli et al. showed that cyclin
E/CDK2-dependent phosphorylation of p27 on threonine 187 facilitates the
formation of a trimeric complex with cyclin E/CDK2 and leads to p27 ubiquitination
(49). In agreement with our findings, recent studies also suggest that CDK may
promote p21 degradation (9, 87). Thus, the activated cyclin E and CDK2 may
decrease the CDK inhibitors p21 and p27 to benefit viral replication. Whether
cyclin E/CDK2 complex directly or indirectly governs the degradation of p21 and
p27 has yet to be clarified.
The pRb phosphorylation by cyclin E/CDK2 may lead to regulation of cellular
and viral genes for Ad replication. Interestingly, Ad-induced cyclin EL expression
is inhibited by a CDK2 chemical inhibitor and CDK2 siRNA (Figs. 7C and 88). It
seems that inhibition of CDK2 interferes in the cyclin E induction via a loop back
regulation (Fig. 9). Previous studies have reported that cyclin E gene is the
downstream target of E2F (19, 53). In our previous work, we showed that the
cyclin E promoter is more active in cancer cells and that the promoter activity is
further enhanced after viral replication (85). We suggest that cyclin E activates the
cyclin E-CDK2-pRb/E2F pathway and cyclin E itself is also one of the targets of
the pathway.
In summary, these results demonstrate that Ad-induced cyclin E plays a
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critical role in Ad replication by activation of CDK2. Our results suggest that cyclin
EL binds to and activates CDK2; subsequently, the active cyclin E/CDK2
phosphorylates the transcription suppressor pRb, which can regulate expression
of multiple cellular and viral genes, including the looping back further increasing
cyclin E production. Therefore, CDK2 activation by cyclin E appears to generate a
suitable environment for viral replication (Fig. 9). Our results not only help to
further reveal the mechanism of Ad replication, but also provide the basis for the
development of future oncolytic vectors. The experiments regarding the novel
oncolytic viruses are ongoing.
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Fig _1_Transgenic cyclin E expression and the infectivity of AdGFP in CHO cells_
(A) 5 x10 5 of CHO cells expressing Myc-tagged wild-type rat cyclin E (cycE-wt) ,
Myc-tagged cyclin E mutant able to bind CDK2 (cycE-SWNQ-A) , or Myc-tagged
cyclin E mutant unable to bind CDK2 (cycE-S180D) were cultured in the presence
or absence of 10 IJg/mL tetracycline for 96 hrs and cell Iysates were analyzed by
Western blot. (8) Wild-type (CHO) and transgenic CHO cells were infected with
AdGFP at an MOl of 10_All fluorescent microscopy is at taken at 48 hr p.i. with an
Olympus IX50 microscope (original magnification of x1 00) .

23

CHO-cycE-wt

CHO

CHO-cycE-SWNQ-A

Adwt

(J..
. ' <:

,
... ,

..

CHO-cycE-S 180D

"

...

~.",
•

,~

, "'

«'

,

Adhz63

Fig . 2. Comparison of viral replication in normal and Myc-cycE transgenic CHO
cells. 5 x10 5 of CHO cells were mocked-infected or infected with AdGFP, Adwt or
Adhz63 at an MOl of 10. CPE was observed at 96 hr p.i. Photographs are
presented in duplicate (original magnification of x100).
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Fig . 3. Cyclin E/CDK2 complex induced by viral infection in A549 cells. (A) A549
cell Iysates were immunoprecipitated with anti-cyclin E antibody (1 :50 dilution) .
Immunocomplexes were analyzed by Western blot with cyclin E and CDK2
antibodies. (8) The ceillysates were immunoprecipitated with anti-CDK2 antibody
and immunoblotted for CDK2 and cyclin E.
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Fig. 4. Effects of viral replication on cellular proteins related to G1/S phase. A549
cells were mock-infected or infected with AdGFP (GFP), Adwt (wt), or Adhz63 (63)
at an MOl of 5. Cells were collected at 24 hr or 48hr p.i., and then analyzed by
Western blot. Cell Iysates were immunoblotted for (A) cyclin E, CDK2 , and actin;
(8) pCDK2 T160 and actin ; and (C) cyclin D, CDK4 , PCNA and actin. Actin was

used as the loading control.
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Fig . 5. Effects of viral replication on pRb and CDK inhibitors. A549 cells were
mock-infected or infected with AdGFP (GFP) , Adwt (wt) , or Adhz63 (63) and
collected at 24 hr or 48 hr p.i. , followed by Western blot analysis . Ceillysates were
immunoblotted for (A) phospho-pRb (p-pRb) at S612 , T821 , S795 and actin ; or (8)
p21 , p27 and actin . Actin was used as the loading control.
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Fig. 6, Effects of roscovitine on CPE and viral production, (A) Cells were treated
with 0 IJM, 5 IJM or 10 IJM of roscovitine (Calbiochem, Darmstadt, Germany) , and
mock-infected or infected with AdGFP, Adwt or Adhz63 at an MOl of 5. All
microscopy is originally at a magnification of x1 00 taken at 48 hr p.i. (8) Viral titers
were determined at 48 hr p.i. with infection unit method , The values represent the
means± S,D, of independent quadruplicate, * P<0.05 compared with the
DMSO-control group , Student's t-test
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Fig. 7. Effects of Ros on viral DNA synthesis, viral capsid proteins, virus-induced
cyclin E and phospho-pRb S612. (A) A549 cells were collected at 0 hr and 24 hr
p.i. Viral DNA synthesis was determined by Southern blot. (8) At 24 hr p.i. , cells
were harvested and cell Iysates were immunoblotted for adenovirus type 5 capsid
proteins, (C) cyclin E (M-20) , pRb S612 , and actin . Actin was used as a loading
control.
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Fig. 8. Effects of CDK2-specific siRNA on oncolytic viral replication. (A) A549 cells
were transfected with 200 nM siRNA duplexes targeting different coding regions
of CDK2. "Mix" represents the mixture of three pairs of siRNA duplexes (#1 to #3).
Cells were harvested at 48 hr after transfection and analyzed by Western blot. (8)
At 48 hr after transfection with CDK2 siRNA duplex (#1) or a negative control
siRNA, cells were infected with Adhz63 at an MOl of 5. Cells were harvested at 24
hr after infection and analyzed by Western blot. (C) The viral titers were
determined at 48 hr p.i. with the infection unit method. The values are means
±S.D. of independent triplicate. * P<0.05 compared with the negative control
group , Student's

t-test.
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Fig. 9. Proposed mechanism of cyclin E function in Ad replication. In Ad-infected
cells, cyclin E binds to and activates CDK2. Subsequently, active pCDK2
phosphorylates the transcription repressor pRb, leading to the downstream
cellular gene expression to provide a suitable environment for the viral replication.
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APPENDIX
List of Abbreviations
Ad

adenovirus

CPE

cytopathic effect

CDK2

cyclin-dependent kinase 2

CHO

Chinese hamster ovary

DMSO

dimethyl sulfoxide

FBS

fetal bovine serum

GFP

green fluorescent protein

IP

immunoprecipitation

MOl

multiplicity of infection

MEM-Alpha

minimal essential medium Alpha

PBS

phosphate buffered saline

Rb

retinoblastoma gene

pRb

retinoblastoma protein

phospho-pRb

phosphorylated pRb

Ros

roscovitine

siRNA

small interfering RNA

Tet

tetracycline

wt

wild-type
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